BIOMARKERS FOR DEMENTIA DIAGNOSIS

VolverGo back

Resultados 36 results. LastUpdate Updated on 18/06/2021 [18:19:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Page1/2 nextPage   results/page


Anti-PHF-Tau Antibodies and Uses Thereof

Publication No.: US2021179696A1 17/06/2021

Applicant:

JANSSEN BIOTECH INC [US]

JP_2020513804_A

Absstract of: US2021179696A1

Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

traducir

DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE

Publication No.: EP3835424A1 16/06/2021

Applicant:

SUMITOMO DAINIPPON PHARMA CO LTD [JP]

US_2021165002_A1

Absstract of: EP3835424A1

The present invention provides a polypeptide consisting of any of the following amino acid sequences and useful for determining Alzheimer's disease:(1) the amino acid sequence shown in SEQ ID NO: 1; and(2) an amino acid sequence resulting from substitution, deletion, addition or insertion of one to several amino acids in the amino acid sequence shown in SEQ ID NO: 1.

traducir

MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS

Publication No.: WO2021113127A2 10/06/2021

Applicant:

SCRIPPS RESEARCH INST [US]
DAVIS RONALD L [US]
LIU ZE [US]
VARKUTI BOGLARKA H [HU]
KEPIRO MIKLOS [HU]
MACMULLEN COURTNEY M [US]

Absstract of: WO2021113127A2

Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from Aβ(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice. The MnMs were demonstrated to protect the mitochondrial population in neurons in an in vivo model of Alzheimer's Disease. Also described is a method for treating a patient suffering from a disorder characterized by dysfunction of neuronal mitostasis, comprising administering to the patient a therapeutically effective amount of a compound (MnM), or a pharmaceutically acceptable salt thereof.

traducir

SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS

Publication No.: EP3829568A1 09/06/2021

Applicant:

ALZHEON INC [US]

CN_112867487_A

Absstract of: WO2020028348A1

Provided herein is the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid- like aggregates, e.g., Alzheimer's disease.

traducir

METHOD FOR ASSISTING WITH DIAGNOSIS OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT, BIOMARKER, REAGENT KIT, AND DEVICE

Publication No.: WO2021107154A1 03/06/2021

Applicant:

FUJIFILM WAKO PURE CHEMICAL CORP [JP]
FUJIFILM WAKO SHIBAYAGI CORP [JP]

Absstract of: WO2021107154A1

The present invention addresses the problem of providing a method for easily assisting with the diagnosis of Alzheimer's disease or mild cognitive impairment, a biomarker, a reagent kit, and a device. The present invention relates to a method for assisting with the diagnosis of Alzheimer's disease, said method including using an amount of phosphatidylserine- and tetraspanin-containing extracellular vesicles as an index to determine whether a subject has Alzheimer's disease. The present invention also relates to a method for assisting with the diagnosis of Alzheimer's disease or mild cognitive impairment, said method including using a ratio of the amount of phosphatidylserine- and tetraspanin-containing extracellular vesicles to the amount of tetraspanin-containing extracellular vesicles as an index to determine whether a subject has Alzheimer's disease or mild cognitive impairment. The present invention further relates to a biomarker, a reagent kit, and a device.

traducir

DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE

Publication No.: US2021165002A1 03/06/2021

Applicant:

SUMITOMO DAINIPPON PHARMA CO LTD [JP]

KR_20210041035_A

Absstract of: US2021165002A1

The present invention provides a polypeptide consisting of any of the following amino acid sequences and useful for determining Alzheimer's disease:(1) the amino acid sequence shown in SEQ ID NO: 1; and(2) an amino acid sequence resulting from substitution, deletion, addition or insertion of one to several amino acids in the amino acid sequence shown in SEQ ID NO: 1.

traducir

BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION

Publication No.: EP3827820A1 02/06/2021

Applicant:

UNIV JOHNS HOPKINS [US]

US_2016038463_A1

Absstract of: EP3827820A1

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism, compulsive behavior, and substance addiction.

traducir

SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS

Publication No.: CN112867487A 28/05/2021

Applicant:

阿尔泽恩股份有限公司

KR_20210039416_PA

Absstract of: WO2020028348A1

Provided herein is the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid- like aggregates, e.g., Alzheimer's disease.

traducir

ANTIBODY THAT SPECIFICALLY RECOGNIZES N TERMINUS OF APP669-x, AND IMMUNOASSAY METHOD

Publication No.: US2021155680A1 27/05/2021

Applicant:

SHIMADZU CORP [JP]

JP_WO2019167830_A1

Absstract of: US2021155680A1

The present invention provides an antibody that recognizes peptides the N-terminals of which start from APP669 (collectively referred to as APP669-x) including the peptide APP669-711 related to an amyloid β (Aβ); a method for measuring APP669-x using said antibody; and a sandwich immunoassay method that is capable of detecting and quantifying a polypeptide to be analyzed with a high sensitivity. An APP669-x N-terminal-recognizing monoclonal antibody that specifically recognizes an N-terminal of an APP669-x peptide. An immunoassay method that uses an APP669-x N-terminal-recognizing monoclonal antibody that specifically recognizes an N-terminal of an APP669-x peptide, and comprises reacting an APP669-x in a sample with the APP669-x N-terminal-recognizing monoclonal antibody to measure the APP669-x.

traducir

PEPTIDE ANALYZING METHOD

Publication No.: US2021156871A1 27/05/2021

Applicant:

SHIMADZU CORP [JP]

Absstract of: US2021156871A1

In the analysis method according to the present invention, a predetermined peptide is separated by immunoprecipitation using an antibody which specifically binds to either an N-terminus or a C-terminus of the predetermined peptide. The separated predetermined peptide is digested with a protease to prepare peptide fragments, and among the peptide fragments, a peptide fragment at a terminus opposite to a terminus binding to the antibody is mass-spectrometrically detected.

traducir

METHOD OF PERFORMING DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE DISEASES IN A SUBJECT

Publication No.: EP3824294A1 26/05/2021

Applicant:

ALZOHIS [FR]

WO_2020016456_PA

Absstract of: WO2020016456A1

The invention is directed to an in vitro method for performing a differential diagnosis of neurodegenerative diseases in a subject, said subject being selected among subjects suffering from Alzheimer's disease, mental depression, dementia with Lewy Body, frontotemporal dementia, and/or vascular dementia. Said method comprises the steps of: (a) determining at least five criteria of said subject, (b) comparing said at least five criteria of said subject with reference values by calculating a global note in relation with each neurodegenerative disease, and (c) determining whether said subject suffers from Alzheimer's disease, mental depression, dementia with Lewy Body, frontotemporal dementia, vascular dementia or mixed dementia.

traducir

GAMMA-SECRETASE INHIBITOR SCREENING ASSAY

Publication No.: WO2021094604A1 20/05/2021

Applicant:

VIB VZW [BE]
KATHOLIEKE UNIV LEUVEN K U LEUVEN R&D [BE]

Absstract of: WO2021094604A1

Current application relates to the field of neurodegenerative diseases. More specifically, the present invention relates to screening methods to identify compounds that can reduce the production of amyloidogenic Amyloid beta fragments. Said compounds can be used in treatments of for example Alzheimer's disease.

traducir

Antibodies to Pyroglutamate Amyloid-β and Uses Thereof

Publication No.: US2021147528A1 20/05/2021

Applicant:

JANSSEN PHARMACEUTICA NV [BE]

US_2020165328_A1

Absstract of: US2021147528A1

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

traducir

DISEASE RISK ASSESSMENT APPARATUS, DISEASE RISK ASSESSMENT METHOD, COMPUTER READABLE MEDIUM, AND FOOD FOR DEMENTIA PREVENTION

Publication No.: US2021148938A1 20/05/2021

Applicant:

UNIV KYUSHU NAT UNIV CORP [JP]
KURUME RES PARK CO LTD [JP]

JP_WO2020090774_A1

Absstract of: US2021148938A1

A disease risk assessment apparatus (100) includes an assessment unit (1) for assessing the risk of developing dementia in a subject, based on the concentration of an amino acid in the blood of the subject. The amino acid includes at least one selected from the group consisting of histidine, phenylalanine, leucine, isoleucine, methionine, threonine, glycine, glutamine, lysine, asparagine, homocysteine, cystathionine, S-adenosylmethionine, and S-adenosylhomocysteine.

traducir

AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY

Publication No.: US2021147522A1 20/05/2021

Applicant:

H LUNDBECK AS [DK]

US_2021061892_A1

Absstract of: US2021147522A1

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

traducir

BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE

Publication No.: JP2021073455A 13/05/2021

Applicant:

エレクトロフォレティクスリミテッド

JP_2018519505_A

Absstract of: WO2016189163A1

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2',3'-cyclic-nucleotide 3'-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

traducir

COMPANION DIAGNOSTIC FOR NSAIDS AND DONEPEZIL FOR TREATING SPECIFIC SUBPOPULATIONS OF PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE

Publication No.: JP2021512287A 13/05/2021

Applicant:

ユニバーシティーオブノーステキサスヘルスサイエンスセンターアットフォートワースUNIVERSITYOFNORTHTEXASHEALTHSCIENCECENTERATFORTWORTH

CA_3088512_A1

Absstract of: WO2019143562A1

The present invention includes a method for identifying a patient response to treatment for Alzheimer's Disease with a non-steroidal anti-inflammatory drug (NSAID) or an acetylcholinesterase (AChE) inhibitor drug comprising: obtaining a blood or serum sample from the patient; determining the presence of a proinflammatory endophenotype in the blood or serum sample of the patient; using the proinflammatory endophenotype to detect treatment response (a responder, a stable, a non-responder or an adverse responder); and treating the patient with the NSAID or the AChE inhibitor if the patient is in the responder or the stable treatment response phenotype group; or preventing a treatment with the NSAID or the AChE inhibitor if the patient is a non-responder or an adverse responder.

traducir

ANTI-TAU ANTIBODIES AND METHODS OF USE

Publication No.: US2021139572A1 13/05/2021

Applicant:

AC IMMUNE SA [CH]
GENENTECH INC [US]

JP_2020511937_A

Absstract of: US2021139572A1

The invention provides anti-Tau antibodies and methods of using the same.

traducir

TAU-BINDING ANTIBODIES

Publication No.: US2021139574A1 13/05/2021

Applicant:

UCB BIOPHARMA SRL [BE]

TN_2017000543_A1

Absstract of: US2021139574A1

The present invention relates to Tau-binding antibodies and binding fragments thereof.

traducir

SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACY

Publication No.: US2021140980A1 13/05/2021

Applicant:

SEPTA THERAPEUTICS INC [CA]

WO_2019134039_PA

Absstract of: US2021140980A1

Methods and compositions useful in treating neurodegenerative disorders are based on septapeptides and extended forms thereof (or portions thereof) that exhibit chemokine activity with respect to microglial cell precursors.

traducir

DIAGNOSTIC COMPOSITIONS FOR PET IMAGING, A METHOD FOR MANUFACTURING THE DIAGNOSTIC COMPOSITION AND ITS USE IN DIAGNOSTICS

Publication No.: JP2021512070A 13/05/2021

Applicant:

エーシー・イミューン・エス・アーライフ・モレキュラー・イメージング・エスアー

EA_202091766_A1

Absstract of: WO2019145293A1

The present application relates to a diagnostic composition comprising: a. a compound of Formula I, b. ethanol, c. water, and d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof. The diagnostic composition can be used in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET). The present invention also relates to a method of preparing the claimed diagnostic composition.

traducir

INHIBITION OF RIP KINASES FOR TREATING NEURODEGENERATIVE DISORDERS

Publication No.: KR20210053303A 11/05/2021

Applicant:

UNIV JOHNS HOPKINS [US]

CN_112638405_A

Absstract of: WO2020047414A1

Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

traducir

METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNs)

Publication No.: US2021130773A1 06/05/2021

Applicant:

NEW YORK STEM CELL FOUND INC [US]
ICAHN SCHOOL MED MOUNT SINAI [US]

JP_2020521472_A

Absstract of: US2021130773A1

The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.

traducir

Peptide immunogen constructs directed against dipeptide repeat proteins from C9ORF72

Publication No.: AU2019354291A1 06/05/2021

Applicant:

UNITED NEUROSCIENCE

CA_3114657_PA

Absstract of: AU2019354291A1

The present disclosure is directed to dipeptide repeat (DPR) peptide immunogen constructs, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed DPR peptide immunogen constructs contain a B cell epitope derived from a DPR protein from C9orf72, including repeats of poly-GA, poly-GP, poly-GR, poly-PR, and poly-PA, linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The B cell epitope portion of the peptide immunogen constructs contain about 10 to about 25 repeats of the respective dipeptide sequence. The disclosed peptide immunogen constructs stimulate the generation of highly specific antibodies directed against the DPR sequences. The disclosed peptide immunogen constructs can be used as an immunotherapy for patients suffering from amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and/or any other condition caused by the presence of DPRs.

traducir

METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES

Nº publicación: US2021132085A1 06/05/2021

Applicant:

GENENTECH INC [US]
ROCHE DIAGNOSTICS OPERATIONS INC [US]

BR_112021000895_A2

Absstract of: US2021132085A1

The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.

traducir

Page1/2 nextPage results/page

punteroimgGo back